JP2012533630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533630A5 JP2012533630A5 JP2012521700A JP2012521700A JP2012533630A5 JP 2012533630 A5 JP2012533630 A5 JP 2012533630A5 JP 2012521700 A JP2012521700 A JP 2012521700A JP 2012521700 A JP2012521700 A JP 2012521700A JP 2012533630 A5 JP2012533630 A5 JP 2012533630A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- substituted
- acceptable salt
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HZXBVTUZHCBOSI-UHFFFAOYSA-N C(COC1)C1OC1CCCCC1 Chemical compound C(COC1)C1OC1CCCCC1 HZXBVTUZHCBOSI-UHFFFAOYSA-N 0.000 description 2
- 0 C[C@](CC1)CC[C@]1C(*c1c(C(O)=O)[s]c(C#CC(C)(C)COC2CCOCC2)c1)=O Chemical compound C[C@](CC1)CC[C@]1C(*c1c(C(O)=O)[s]c(C#CC(C)(C)COC2CCOCC2)c1)=O 0.000 description 2
- STYZOEAXSMEXGV-PDPKZZNXSA-N CC(CC1)CCC1C(N(CCOc1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)Cc2nc(S[C@H](CC3)CC[C@@H]3N(C([C@H]3CC[C@H](C)CC3)=O)c3c(C(O)=O)[s]c(C#CC(C)(C)C)c3)ncc2)c1)=O Chemical compound CC(CC1)CCC1C(N(CCOc1ncccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)Cc2nc(S[C@H](CC3)CC[C@@H]3N(C([C@H]3CC[C@H](C)CC3)=O)c3c(C(O)=O)[s]c(C#CC(C)(C)C)c3)ncc2)c1)=O STYZOEAXSMEXGV-PDPKZZNXSA-N 0.000 description 1
- KFVRDWIDIHRPMV-RZZSZECMSA-N CC(CC1)CCC1C(N([C@H](CC1)CC[C@@H]1Oc1nccc(C(NC2CCN(C)CC2)=O)c1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound CC(CC1)CCC1C(N([C@H](CC1)CC[C@@H]1Oc1nccc(C(NC2CCN(C)CC2)=O)c1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O KFVRDWIDIHRPMV-RZZSZECMSA-N 0.000 description 1
- HQJJNPLFWPONOJ-AULMGXOSSA-N CC(CC1)CCC1C(N([C@H](CC1)CC[C@H]1Oc1cc(CN(C)C)ccn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound CC(CC1)CCC1C(N([C@H](CC1)CC[C@H]1Oc1cc(CN(C)C)ccn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O HQJJNPLFWPONOJ-AULMGXOSSA-N 0.000 description 1
- QOMDMGYFGNODAG-NHIIVYHSSA-N CCc(cn1)cnc1O[C@H](CC1)CC[C@@H]1N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)Cc2nc(O[C@H](CC3)CC[C@H]3N(C([C@H]3CC[C@H](C)CC3)=O)c3c(C(O)=O)[s]c(C#CC(C)(C)C)c3)ncc2)c1 Chemical compound CCc(cn1)cnc1O[C@H](CC1)CC[C@@H]1N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)Cc2nc(O[C@H](CC3)CC[C@H]3N(C([C@H]3CC[C@H](C)CC3)=O)c3c(C(O)=O)[s]c(C#CC(C)(C)C)c3)ncc2)c1 QOMDMGYFGNODAG-NHIIVYHSSA-N 0.000 description 1
- FOEMIZSFFWGXHX-UHFFFAOYSA-N CSc1ncccn1 Chemical compound CSc1ncccn1 FOEMIZSFFWGXHX-UHFFFAOYSA-N 0.000 description 1
- DCVXXBSOALSOCT-ACRUOGEOSA-N C[C@@H](CCOc1cnccc1)N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1 Chemical compound C[C@@H](CCOc1cnccc1)N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1 DCVXXBSOALSOCT-ACRUOGEOSA-N 0.000 description 1
- JIMBKAVWHTWXQJ-UFYCRDLUSA-N C[C@@H](CCOc1ncccn1)N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1 Chemical compound C[C@@H](CCOc1ncccn1)N(C([C@H]1CC[C@H](C)CC1)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1 JIMBKAVWHTWXQJ-UFYCRDLUSA-N 0.000 description 1
- CKHSTWDUMMKPEL-MEMLXQNLSA-N C[C@H](CC1)CC[C@@H]1C(N(C(CC1)CCN1S(c1cnccc1)(=O)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N(C(CC1)CCN1S(c1cnccc1)(=O)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O CKHSTWDUMMKPEL-MEMLXQNLSA-N 0.000 description 1
- ROHZXBGOWBVRHI-ACRUOGEOSA-N C[C@H](CC1)CC[C@@H]1C(N([C@@H](CC1)CN1S(c1cnccc1)(=O)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@@H](CC1)CN1S(c1cnccc1)(=O)=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O ROHZXBGOWBVRHI-ACRUOGEOSA-N 0.000 description 1
- LVAVEGHVIHKCNJ-IFSQOONMSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1OC(C=CN1)=NC1=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1OC(C=CN1)=NC1=O)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O LVAVEGHVIHKCNJ-IFSQOONMSA-N 0.000 description 1
- COACHVJQVZURCG-IFSQOONMSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc(nn1)ccc1O)c1c(C(O)=O)[s]c(C#CC2(CCC2)C(F)(F)F)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc(nn1)ccc1O)c1c(C(O)=O)[s]c(C#CC2(CCC2)C(F)(F)F)c1)=O COACHVJQVZURCG-IFSQOONMSA-N 0.000 description 1
- HUEMGDNXEQTFAN-PBCKQTSCSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1c(CN(CC2)CC2N(C)C)ccnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1c(CN(CC2)CC2N(C)C)ccnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O HUEMGDNXEQTFAN-PBCKQTSCSA-N 0.000 description 1
- CDPLEDLRPNRMEH-QWZLJSJVSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1cc(CN(C)C)ccn1)c1c(C(O)=O)[s]c(C#CC2(CC2)C(F)(F)F)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1cc(CN(C)C)ccn1)c1c(C(O)=O)[s]c(C#CC2(CC2)C(F)(F)F)c1)=O CDPLEDLRPNRMEH-QWZLJSJVSA-N 0.000 description 1
- KVOUESFXZQCLLP-MVBYDDMTSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1cc(CN(C)C)cnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1cc(CN(C)C)cnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O KVOUESFXZQCLLP-MVBYDDMTSA-N 0.000 description 1
- DWVPQAZEQIOEDS-MUGGOUMZSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1nc(CN2CCOCC2)ccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1nc(CN2CCOCC2)ccc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O DWVPQAZEQIOEDS-MUGGOUMZSA-N 0.000 description 1
- UUCQLJNFHZYTON-MVBYDDMTSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1nccc(CN(C)C)c1)c1c(C(O)=O)[s]c(C#CC2(CCC2)C(F)(F)F)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1nccc(CN(C)C)c1)c1c(C(O)=O)[s]c(C#CC2(CCC2)C(F)(F)F)c1)=O UUCQLJNFHZYTON-MVBYDDMTSA-N 0.000 description 1
- SXKJFTGLURDMII-CHDDOINTSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1ncncc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Oc1ncncc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O SXKJFTGLURDMII-CHDDOINTSA-N 0.000 description 1
- HWFPVIWQOUDLIC-REODPECZSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1S/C(/NN)=C/N)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1S/C(/NN)=C/N)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O HWFPVIWQOUDLIC-REODPECZSA-N 0.000 description 1
- ZGGSKCQZMYXDOB-UBBSCCEASA-O C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1[nH+][nH]cn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1[nH+][nH]cn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O ZGGSKCQZMYXDOB-UBBSCCEASA-O 0.000 description 1
- OYMKPOCENOJCMQ-KBQPQWKXSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1ccccn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1ccccn1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O OYMKPOCENOJCMQ-KBQPQWKXSA-N 0.000 description 1
- JCGVRQXBRNGKFH-YSXIEMCBSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1nnc(C)[o]1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@@H]1Sc1nnc(C)[o]1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O JCGVRQXBRNGKFH-YSXIEMCBSA-N 0.000 description 1
- GSRQLELLPZXJEL-AGJYPBCPSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Oc1cccnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Oc1cccnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O GSRQLELLPZXJEL-AGJYPBCPSA-N 0.000 description 1
- HUDMIVJEYSDLFN-SVRSMAFJSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Oc1cncnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Oc1cncnc1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O HUDMIVJEYSDLFN-SVRSMAFJSA-N 0.000 description 1
- HSSVKHZTWZIETE-PVPVSOICSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Sc1ncc[s]1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CC1)CC[C@H]1Sc1ncc[s]1)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O HSSVKHZTWZIETE-PVPVSOICSA-N 0.000 description 1
- HYGZCHJAYASXHA-YDHSSHFGSA-N C[C@H](CC1)CC[C@@H]1C(N([C@H](CCOc1ccccn1)OC1=O)c2c1[s]c(C#CC(C)(C)C)c2)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(N([C@H](CCOc1ccccn1)OC1=O)c2c1[s]c(C#CC(C)(C)C)c2)=O HYGZCHJAYASXHA-YDHSSHFGSA-N 0.000 description 1
- ICVBBGCKGONZJH-HDJSIYSDSA-N C[C@H](CC1)CC[C@@H]1[IH](N(C)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O Chemical compound C[C@H](CC1)CC[C@@H]1[IH](N(C)c1c(C(O)=O)[s]c(C#CC(C)(C)C)c1)=O ICVBBGCKGONZJH-HDJSIYSDSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22736709P | 2009-07-21 | 2009-07-21 | |
| US61/227,367 | 2009-07-21 | ||
| US24091109P | 2009-09-09 | 2009-09-09 | |
| US61/240,911 | 2009-09-09 | ||
| US35946610P | 2010-06-29 | 2010-06-29 | |
| US61/359,466 | 2010-06-29 | ||
| PCT/US2010/042394 WO2011011303A1 (en) | 2009-07-21 | 2010-07-19 | Inhibitors of flaviviridae viruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015160807A Division JP2015205940A (ja) | 2009-07-21 | 2015-08-18 | フラビウイルス科ウイルスの阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012533630A JP2012533630A (ja) | 2012-12-27 |
| JP2012533630A5 true JP2012533630A5 (OSRAM) | 2015-02-26 |
| JP5841531B2 JP5841531B2 (ja) | 2016-01-13 |
Family
ID=42711860
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012521700A Expired - Fee Related JP5841531B2 (ja) | 2009-07-21 | 2010-07-19 | フラビウイルス科ウイルスの阻害剤 |
| JP2015160807A Withdrawn JP2015205940A (ja) | 2009-07-21 | 2015-08-18 | フラビウイルス科ウイルスの阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015160807A Withdrawn JP2015205940A (ja) | 2009-07-21 | 2015-08-18 | フラビウイルス科ウイルスの阻害剤 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US8569302B2 (OSRAM) |
| EP (1) | EP2475657B1 (OSRAM) |
| JP (2) | JP5841531B2 (OSRAM) |
| KR (1) | KR20120051022A (OSRAM) |
| CN (1) | CN102471327A (OSRAM) |
| AP (1) | AP3409A (OSRAM) |
| AR (1) | AR077765A1 (OSRAM) |
| AU (1) | AU2010276441B2 (OSRAM) |
| CA (1) | CA2767088C (OSRAM) |
| CL (1) | CL2012000147A1 (OSRAM) |
| CO (1) | CO6491049A2 (OSRAM) |
| CR (1) | CR20120081A (OSRAM) |
| DK (1) | DK2475657T3 (OSRAM) |
| EA (1) | EA020816B1 (OSRAM) |
| EC (1) | ECSP12011684A (OSRAM) |
| ES (1) | ES2427342T3 (OSRAM) |
| IL (1) | IL217243A (OSRAM) |
| MX (1) | MX2012000959A (OSRAM) |
| NZ (1) | NZ597528A (OSRAM) |
| PE (1) | PE20120666A1 (OSRAM) |
| SG (1) | SG177709A1 (OSRAM) |
| TW (1) | TW201116525A (OSRAM) |
| UY (1) | UY32793A (OSRAM) |
| WO (1) | WO2011011303A1 (OSRAM) |
| ZA (1) | ZA201200940B (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2475657T3 (da) * | 2009-07-21 | 2013-09-23 | Gilead Sciences Inc | 5-Alkynylthien-2-ylcarboxylsyrer som inhibitorer af flaviviridae-vira |
| KR20120081123A (ko) | 2009-09-09 | 2012-07-18 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리대 바이러스의 억제제 |
| BR112012006180A2 (pt) | 2009-09-21 | 2015-09-08 | Gilead Sciences Inc | processos e intermediários para a preparação de análogos de 1'-substituido carba-nucleosídeo |
| ES2626150T3 (es) | 2010-01-15 | 2017-07-24 | Gilead Sciences, Inc. | Inhibidores de virus flaviviridae |
| NZ600816A (en) * | 2010-01-15 | 2014-08-29 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| AU2011276526A1 (en) * | 2010-06-28 | 2013-01-10 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
| SG186830A1 (en) | 2010-07-22 | 2013-02-28 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
| MA34462B1 (fr) | 2010-07-22 | 2013-08-01 | Novartis Ag | Composes de thiophene 2,3,5- trisubstitues et leurs utilisations |
| PT2734515E (pt) * | 2011-07-13 | 2016-03-11 | Gilead Sciences Inc | Derivados de ácido tiofen-2-carboxílico úteis como inibidores de vírus flaviviridae |
| HUE032306T2 (en) | 2012-06-26 | 2017-09-28 | Bayer Pharma AG | N- [4- (quinolin-4-yloxy) cyclohexyl (methyl)] (hetero) arylcarboxamides as androgen receptor antagonists, their production and use as pharmaceutical products |
| US8841340B2 (en) | 2012-08-17 | 2014-09-23 | Gilead Sciences, Inc. | Solid forms of an antiviral compound |
| US8927741B2 (en) | 2012-08-17 | 2015-01-06 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| US8759544B2 (en) * | 2012-08-17 | 2014-06-24 | Gilead Sciences, Inc. | Synthesis of an antiviral compound |
| CN102964295B (zh) * | 2012-12-17 | 2014-08-20 | 寿光富康制药有限公司 | 一种2-取代-4-（哌啶基甲基）吡啶的制备方法 |
| EP2762124A1 (en) * | 2013-01-31 | 2014-08-06 | IP Gesellschaft für Management mbH | Packaging comprising administration units of polymorphs, amorphous forms or solvates |
| US9492438B2 (en) * | 2014-07-25 | 2016-11-15 | Bette Pollard | Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system |
| TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| BR122020020217B1 (pt) | 2015-09-16 | 2021-08-17 | Gilead Sciences, Inc | Uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por arenaviridae |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| PL3464336T3 (pl) | 2016-06-01 | 2022-05-16 | Athira Pharma, Inc. | Związki |
| EP4331677A3 (en) | 2017-03-14 | 2024-05-29 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| CA3178212A1 (en) | 2017-05-01 | 2018-11-08 | Gilead Sciences, Inc. | Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| PL3651734T3 (pl) | 2017-07-11 | 2025-03-31 | Gilead Sciences, Inc. | Kompozycje zawierające inhibitor polimerazy rna i cyklodekstrynę do leczenia infekcji wirusowych |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| US11660307B2 (en) | 2020-01-27 | 2023-05-30 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
| EP4132651A1 (en) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| TW202532084A (zh) | 2020-05-29 | 2025-08-16 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| WO2021262826A2 (en) | 2020-06-24 | 2021-12-30 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| PT4204421T (pt) | 2020-08-27 | 2024-06-25 | Gilead Sciences Inc | Compostos e métodos para o tratamento de infeções virais |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| JP2025508942A (ja) | 2022-03-02 | 2025-04-10 | ギリアード サイエンシーズ， インコーポレイテッド | ウイルス感染症の治療のための化合物及び方法 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5861421A (en) * | 1995-12-21 | 1999-01-19 | Smithkline Beecham Corporation | 4,4-(disubstituted) cyclohexan-1-one monomers and related compounds |
| US20020002199A1 (en) * | 1998-03-12 | 2002-01-03 | Lone Jeppesen | Modulators of protein tyrosine phosphatases (ptpases) |
| US20050119332A1 (en) * | 1998-03-12 | 2005-06-02 | Lone Jeppesen | Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases) |
| JP2005500287A (ja) | 2001-06-11 | 2005-01-06 | シャイアー バイオケム インコーポレイテッド | Ｆｌａｖｉｖｉｒｕｓ感染の処置または予防のための化合物および方法 |
| PT1401825E (pt) * | 2001-06-11 | 2009-10-23 | Virochem Pharma Inc | Compostos e métodos para o tratamento ou para a prevenção de infecções com flavivírus |
| CN100413861C (zh) * | 2002-12-10 | 2008-08-27 | 维勒凯姆制药股份有限公司 | 用于治疗或预防黄病毒感染的化合物 |
| MXPA05006196A (es) | 2002-12-10 | 2006-01-27 | Virochem Pharma Inc | Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus. |
| DE10359791A1 (de) * | 2003-12-19 | 2005-07-21 | Bayer Healthcare Ag | Substituierte Thiophene |
| WO2005081954A2 (en) * | 2004-02-25 | 2005-09-09 | Wyeth | Inhibitors of protein tyrosine phosphatase 1b |
| EP1732919A1 (en) * | 2004-03-30 | 2006-12-20 | Chiron Corporation | Substituted thiophene derivatives as anti-cancer agents |
| DE102004061746A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
| DE102005028077A1 (de) | 2004-12-22 | 2006-07-13 | Aicuris Gmbh & Co. Kg | Alkinyl-substituierte Thiophene |
| BRPI0610283A2 (pt) * | 2005-05-13 | 2010-10-19 | Virochem Pharma Inc | composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica |
| TW200801022A (en) | 2006-02-15 | 2008-01-01 | Sanofi Aventis | Novel amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments |
| SG176488A1 (en) | 2006-11-15 | 2011-12-29 | Virochem Pharma Inc | Thiophene analogues for the treatment or prevention of flavivirus infections |
| JP2010510191A (ja) * | 2006-11-17 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | 抗ウイルス剤としての２−カルボキシチオフェン誘導体 |
| AU2009322400A1 (en) | 2008-12-03 | 2011-06-30 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
| DK2475657T3 (da) * | 2009-07-21 | 2013-09-23 | Gilead Sciences Inc | 5-Alkynylthien-2-ylcarboxylsyrer som inhibitorer af flaviviridae-vira |
| KR20120081123A (ko) * | 2009-09-09 | 2012-07-18 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리대 바이러스의 억제제 |
| WO2011068715A1 (en) | 2009-11-25 | 2011-06-09 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections |
| ES2626150T3 (es) * | 2010-01-15 | 2017-07-24 | Gilead Sciences, Inc. | Inhibidores de virus flaviviridae |
| NZ600816A (en) * | 2010-01-15 | 2014-08-29 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| AU2011276526A1 (en) | 2010-06-28 | 2013-01-10 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of Flavivirus infections |
-
2010
- 2010-07-19 DK DK10735402.9T patent/DK2475657T3/da active
- 2010-07-19 AP AP2012006085A patent/AP3409A/xx active
- 2010-07-19 EA EA201290053A patent/EA020816B1/ru not_active IP Right Cessation
- 2010-07-19 KR KR1020127004379A patent/KR20120051022A/ko not_active Withdrawn
- 2010-07-19 MX MX2012000959A patent/MX2012000959A/es active IP Right Grant
- 2010-07-19 PE PE2012000069A patent/PE20120666A1/es not_active Application Discontinuation
- 2010-07-19 CA CA2767088A patent/CA2767088C/en not_active Expired - Fee Related
- 2010-07-19 TW TW099123657A patent/TW201116525A/zh unknown
- 2010-07-19 JP JP2012521700A patent/JP5841531B2/ja not_active Expired - Fee Related
- 2010-07-19 SG SG2012004115A patent/SG177709A1/en unknown
- 2010-07-19 UY UY0001032793A patent/UY32793A/es not_active Application Discontinuation
- 2010-07-19 EP EP10735402.9A patent/EP2475657B1/en active Active
- 2010-07-19 US US12/838,684 patent/US8569302B2/en active Active
- 2010-07-19 AR ARP100102629A patent/AR077765A1/es unknown
- 2010-07-19 WO PCT/US2010/042394 patent/WO2011011303A1/en not_active Ceased
- 2010-07-19 AU AU2010276441A patent/AU2010276441B2/en not_active Ceased
- 2010-07-19 CN CN2010800328463A patent/CN102471327A/zh active Pending
- 2010-07-19 ES ES10735402T patent/ES2427342T3/es active Active
- 2010-07-19 NZ NZ597528A patent/NZ597528A/en not_active IP Right Cessation
-
2011
- 2011-12-28 IL IL217243A patent/IL217243A/en not_active IP Right Cessation
-
2012
- 2012-01-17 CO CO12006267A patent/CO6491049A2/es active IP Right Grant
- 2012-01-19 CL CL2012000147A patent/CL2012000147A1/es unknown
- 2012-02-08 ZA ZA2012/00940A patent/ZA201200940B/en unknown
- 2012-02-16 EC ECSP12011684 patent/ECSP12011684A/es unknown
- 2012-02-16 CR CR20120081A patent/CR20120081A/es unknown
-
2013
- 2013-09-25 US US14/037,296 patent/US20140030223A1/en not_active Abandoned
-
2015
- 2015-08-18 JP JP2015160807A patent/JP2015205940A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012533630A5 (OSRAM) | ||
| US10738035B2 (en) | Hepatitis B antiviral agents | |
| ES2897913T3 (es) | Compuestos de piridona tetracíclicos como antivirales | |
| JP2020527588A5 (OSRAM) | ||
| HRP20140370T1 (hr) | 1'-supstituirani-karba-nukleozid prolijekovi za antivirusni tretman | |
| JP2014520822A5 (OSRAM) | ||
| RU2016122908A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| JP2019527731A (ja) | Ｈｂｖ感染の治療のための新規治療薬 | |
| CN102480957A (zh) | 治疗癌症及非肿瘤病症的方法 | |
| JP2013517291A5 (OSRAM) | ||
| JP2010510233A5 (OSRAM) | ||
| JP2010527373A5 (OSRAM) | ||
| JP2020507582A5 (OSRAM) | ||
| JP2011520906A5 (OSRAM) | ||
| JP2015512860A5 (OSRAM) | ||
| JP2010510234A5 (OSRAM) | ||
| JP2012528166A5 (OSRAM) | ||
| RU2015110082A (ru) | Соединения дигидропиримидина и их применение в фармацевтических препаратах | |
| WO2016161268A1 (en) | Hepatitis b antviral agents | |
| JP2011518835A5 (OSRAM) | ||
| RU2017126995A (ru) | Производные и способы лечения инфекций гапатита в | |
| JP2013507439A5 (OSRAM) | ||
| JP2008514732A5 (OSRAM) | ||
| JP2011006480A5 (OSRAM) | ||
| JP2013538230A5 (OSRAM) |